四环医药(00460.HK)：附属减重药物临床试验申请获批

阿斯达克财经08-30

四环医药(00460.HK) 公布，旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准，这是该产品继成人2型糖尿病患者的血糖控制适应症后，获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2463622013?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","is_english":false,"pubTime":"2024-08-30 12:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2463622013","market":"fut","top_or_hot":-1,"title":"四环医药(00460.HK)：附属减重药物临床试验申请获批","media":"阿斯达克财经","content":"<div>\n<p>四环医药(00460.HK) 公布，旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准，这是该产品继成人2型糖尿病患者的血糖控制适应症后，获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377607/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>四环医药(00460.HK)：附属减重药物临床试验申请获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n四环医药(00460.HK)：附属减重药物临床试验申请获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-30 12:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377607/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>四环医药(00460.HK) 公布，旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准，这是该产品继成人2型糖尿病患者的血糖控制适应症后，获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377607/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1600","symbol_name":"工业大麻","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1377607/latest-news/AAFN","article_id":"2463622013","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463622013","pubTimestamp":1724991120,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"四环医药(00460.HK) 公布，旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准，这是该产品继成人2型糖尿病患者的血糖控制适应症后，获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1600":"工业大麻","BK1515":"抗疫概念","BK1191":"制药","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK1593":"医美概念股","03347":"泰格医药","00460":"四环医药","BK1583":"高瓴概念"},"translate_title":"Sihuan Pharmaceutical (00460. HK): Application for clinical trial of subsidiary weight loss drugs approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1,"03347":1},"content_text":"四环医药(00460.HK) 公布，旗下非全资附属公司开发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获国家药监局批准，这是该产品继成人2型糖尿病患者的血糖控制适应症后，获得临床试验批准的第二个适应症。该产品同时也是公司首个获得临床试验批准的减重药物。(vc/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-29 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.0","shortVersion":"4.28.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463622013"}